Physician profile
Jaime E Trujillo
NPI 1073564399
$2,325.78
in general payments reported to CMS, 2019-2025
24 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.62 · 2020: $215 · 2021: $256 · 2022: $154 · 2023: $610 · 2024: $498 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $564.90 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $350.85 | 2019-2025 | Jardiance, Mounjaro |
| Amgen INC. | $266.42 | 2022-2025 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $157.95 | 2020-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $125.86 | 2019-2025 | Omnipod |
| Medtronic Minimed, INC. | $117.09 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $113.91 | 2020-2022 | |
| Abbvie INC. | $109.29 | 2021-2025 | Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $95.83 | 2022-2024 | |
| Abbott Laboratories | $53.52 | 2021-2025 | Eterna, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.52 | 2023-2024 | Jardiance |
| Horizon Therapeutics Plc | $51.18 | 2021-2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $41.18 | 2021 | |
| Mannkind Corporation | $38.63 | 2023 | Afrezza |
| Boston Scientific Corporation | $26.25 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $24.86 | 2025 | Twiist |
| Cequr Corporation | $23.12 | 2025 | Cequr Simplicity |
| Corcept Therapeutics | $20.00 | 2023 | Korlym |
| Medtronic, INC. | $18.68 | 2021 | |
| Esperion Therapeutics, INC. | $17.67 | 2024 | Nexletol |
| Exact Sciences Corporation | $15.36 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $14.08 | 2020 | |
| Pfizer INC. | $13.68 | 2025 | |
| Tandem Diabetes Care, INC. | $12.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Trujillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.